New drug duo aims to tackle tough lymphoma

NCT ID NCT06492837

Recruiting now Disease control Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining two drugs, mosunetuzumab and zanubrutinib, can help people with follicular lymphoma whose cancer has returned or stopped responding to previous treatment. The study will enroll 56 participants and measure how many achieve a complete response (cancer disappearance) after treatment. The goal is to find a more effective salvage therapy for this type of blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mosunetuzumab and Zanubrutinib (drug combination)
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is an early-phase (phase 2) trial with only 56 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Locations

A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia
RECRUITING

Palermo, Italy
A.O.U. Città della Salute e della Scienza di Torino, S.C.Ematologia
NOT_YET_RECRUITING

Torino, Italy
AOU Maggiore della Carità di Novara, SCDU Ematologia
RECRUITING

Novara, Italy
AOU Ospedali Riuniti, Clinica di Ematologia
RECRUITING

Ancona, Italy
AOU SS. Antonio e Biagio e Cesare Arrigo, SCDU Ematologia
RECRUITING

Alessandria, Italy
ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
RECRUITING

Milan, Italy
ASST Spedali Civili di Brescia, Ematologia
RECRUITING

Brescia, Italy
Azienda Ospedaliera S.Giuseppe Moscati, S.C. Ematologia e Trapianto emopoietico
RECRUITING

Avellino, Italy
Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
RECRUITING

Florence, Italy
Azienda Ospedaliera Universitaria Policlinico - S. Marco, UOC di Ematologia
RECRUITING

Catania, Italy
Azienda USL Piacenza, UOC Ematologia e Centro Trapianti
RECRUITING

Piacenza, Italy
Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia
RECRUITING

Reggio Emilia, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia
RECRUITING

Milan, Italy
Fondazione IRCCS San Gerardo dei Tintori, Ematologia
RECRUITING

Monza, Italy
Fondazione del Piemonte per l'Oncologia - IRCCS, Ematologia
RECRUITING

Candiolo, Torino, Italy
IRCCS Istituto Tumori Giovanni Paolo II, U.O.C Ematologia
RECRUITING

Bari, Italy
Liverpool Hospital
RECRUITING

Liverpool, Australia
Ospedale Ca' Foncello, S.C di Ematologia
RECRUITING

Treviso, Italy
Ospedale degli Infermi di Rimini, U.O. di Ematologia
RECRUITING

Rimini, Italy
Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli"
RECRUITING

Bologna, Italy
Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione
RECRUITING

Roma, Italy
Princess Alexandra Hospital
RECRUITING

Woolloongabba, Australia
Royal Adelaide Hospital
RECRUITING

Adelaide, Australia
St. Vincent Hospital Melbourne
RECRUITING

Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.